Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. (JNCE) Revenue
Annual & quarterly revenue history · segment & region breakdown
JNCE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsJounce Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.08B, an increase of 204.75% year-over-year from $0.08B in FY2022.
Revenue trend
2022 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.08B | +$0.06B | +204.75% |
| 2021-12-31 | $0.03B | -$0.04B | -56.84% |
| 2020-12-31 | $0.06B | -$0.09B | -57.84% |
| 2019-12-31 | $0.15B | +$0.08B | +126.79% |
| 2018-12-31 | $0.07B | -$0.01B | -8.99% |
| 2017-12-31 | $0.07B | +$0.03B | +92.61% |
| 2016-12-31 | $0.04B | +$0.04B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare JNCE revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Jounce Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Jounce Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Jounce Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
JNCE revenue · 4 questionsJNCE's trailing twelve-month (TTM) revenue is $0.08B. That is an increase of 204.75% year-over-year from $0.08B in FY2022.
▸ Source: FMP · Jounce Therapeutics, Inc. SEC filings · GAAP · Jounce Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026